Skip to main content

Table 2 RV volumetric parameters at baseline, 6 and 12 months (mean ± SD) in the 2 treatment arms.

From: Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload

  

Baseline

6 Months

12 Months

p

Deferiprone

     
 

T2*, ms

13.0 (32)

15.4 (38)

16.5 (38)

< 0.001

 

RVEDV, mL

122.5 ± 24.9

123.2 ± 26.0

121.3 ± 24.9

0.61

 

RVESV, mL

37.7 ± 11.7

35.9 ± 11.7

34.2 ± 11.3

0.009

 

RVSV, mL

84.7 ± 16.5

87.3 ± 16.5

87.1 ± 17.0

0.16

 

RVEF, %

69.6 ± 5.2

71.4 ± 4.7

72.2 ± 5.3

0.001

Deferoxamine

     
 

T2*, ms

13.3 (30)

14.4 (37)

15 (39)

<0.001

 

RVEDV, mL

124.7 ± 27.7

124.4 ± 26.2

128 ± 32.1

0.17

 

RVESV, mL

38.1 ± 12.6

37.2 ± 12.5

39.1 ± 13.0

0.38

 

RVSV, mL

86.7 ± 18.0

87.0 ± 15.5

88.9 ± 21.3

0.25

 

RVEF, %

70.0 ± 5.8

70.8 ± 5.2

69.9 ± 4.6

0.93

  1. The T2* values show the geometric mean and CV. The p value reflects the change from baseline to 12 months.